Togaviridae Or Flaviviridae, Except Hepatitis C Virus (e.g., Yellow Fever Virus, Bovine Viral Diarrhea Virus, Dengue Virus, Equine Viral Arteritis Virus, Equine Encephalitis Virus, Japanese B Encephalitis Virus, Sindbis Virus, Flavivirus, Etc.) Patents (Class 424/218.1)
-
Patent number: 9238843Abstract: Disclosed are methods and compositions for identifying viral-specific polynucleotide sequences in a biological sample, and particularly in samples of veterinary origin. Also disclosed are oligonucleotide primer pairs, as well as labeled oligonucleotide detection probes useful in detecting the presence of one or more particular species, strains, types, or subtypes of one or more mammalian pathogens of viral origin, as well as systems, diagnostic kits and articles of manufacture comprising virus-specific primers and labeled detection probes, including those useful in identifying viral components of a multivalent vaccine, and quantitating the potency of particular attenuated, live viruses that comprise a livestock vaccine. In certain embodiments, real-time, quantitative PCR methods have been utilized to identify and distinguish between the three known genetic subtypes of bovine viral diarrhea viruses (BVDV-1a, BVDV-1b, and BVDV-2) in a multivalent bovid shipping fever vaccine.Type: GrantFiled: December 21, 2011Date of Patent: January 19, 2016Assignee: Eli Lilly and CompanyInventors: Dale Wade Weise, James Robert Harris
-
Patent number: 9228203Abstract: This invention relates to bicistronic flavivirus vectors, methods of using such vectors in the prevention and treatment of disease, and methods of making such vectors.Type: GrantFiled: July 15, 2013Date of Patent: January 5, 2016Assignee: Sanofi Pasteur Biologics, LLCInventors: Simon Delagrave, Nathan Brown, Harold Kleanthous, Farshad Guirakhoo, Alexander A. Rumyantsev
-
Patent number: 9211323Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4.Type: GrantFiled: May 28, 2010Date of Patent: December 15, 2015Assignee: TAKEDA VACCINES, INC.Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
-
Patent number: 9198964Abstract: The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent immune responses. In preferred embodiments of the compositions described herein, the DEN4 protein component is a dimeric form of DEN4. The compositions are designed to be acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. Also provided herein are methods of inducing a protective immune response in a human patient population by administering the compositions described herein to the patients.Type: GrantFiled: October 27, 2011Date of Patent: December 1, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Beth-Ann Griswold Coller, Vidya B. Pai, D. Elliot Parks, Michele Yelmene, Andrew J. Bett, Timothy Martyak
-
Patent number: 9173575Abstract: A method for determining haemodynamic performance in a human or animal subject comprises receiving at a processor data representing haemodynamic variables measured from the subject over time. The haemodynamic variables comprise at least two of Systemic Perfusion Pressure (SPP), Systemic Vascular Resistance (SVR), Cardiac Output (CO), Heart Rate (HR) and Stroke Volume (SV). The data are processed to produce a display signal for causing a display device to present a visual mapping relating the haemodynamic variables according to the relationship SPP=CO×SVR and the visual mapping is displayed on a display device. The visual mapping may be corrected Heart Rate (HR) or include a second mapping which facilitates an adjustment to take account of HR.Type: GrantFiled: June 17, 2010Date of Patent: November 3, 2015Inventor: Stephen Woodford
-
Patent number: 9139618Abstract: The present invention relates to Salmonid alphavirus E2-protein expressed in a bacterial expression system, its use in medicine, vaccines comprising such protein, methods for the preparation of such proteins and methods for the preparation of vaccines comprising such proteins.Type: GrantFiled: December 28, 2011Date of Patent: September 22, 2015Assignee: Intervet Inc.Inventor: Stephane Villoing
-
Patent number: 9132184Abstract: This invention provides pharmaceutical compositions, such as vaccines, and methods of making and using such compositions.Type: GrantFiled: November 7, 2007Date of Patent: September 15, 2015Assignee: Sanofi Pasteur Biologics, LLCInventors: Daniel C. Vellom, James E. Woiszwillo, Paul DeGeorge, Peter Ciarametaro, Amy Woiszwillo, Dara O'Neil, Jennifer Woiszwillo, Cole Woiszwillo
-
Patent number: 9052321Abstract: Provided herein is a mammalian cell transformed to contain a plasmid encoding a T7 or SP6 promoter operably linked to one or more HCV genes, a subgenomic replicon from a flavivirus and a cytoplasmic T7 and SP6 RNA amplification system. Also provided herein are isolated replication-competent HCV particles produced by the method comprising the steps of providing a transformed mammalian cell according to the first embodiment, culturing the cell, and recovering the replication-competent HCV particles from the cell culture. Provided herein are isolated HCV structural proteins produced by the method comprising the steps of providing a transformed mammalian cell according to the first embodiment, culturing the cell, and recovering the HCV structural proteins from the cell culture.Type: GrantFiled: September 28, 2009Date of Patent: June 9, 2015Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Bertrand Saunier, Miriam Triyatni, Edward A. Berger
-
Patent number: 9005633Abstract: A method to prepare inactivate viral vaccine by exposing the virus to a predetermined concentration of an inactivating psoralen, and a preselected intensity of ultraviolet radiation for a time period sufficiently long to render the virus non-infectious but less than that which would result in degradation of its antigenic characteristics.Type: GrantFiled: July 17, 2010Date of Patent: April 14, 2015Assignee: The United States of America as Represented by the Secretary of the Navy.Inventors: Tadeusz J. Kochel, Ryan C. Maves, Kevin Porter
-
Patent number: 9000141Abstract: Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glycoprotein cross-reactive epitopes and flavivirus E-glycoprotein cross-reactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.Type: GrantFiled: September 28, 2010Date of Patent: April 7, 2015Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Gwong-Jen J. Chang, Wayne D. Crill
-
Patent number: 8993744Abstract: Disclosed herein are computationally optimized broadly reactive dengue virus E polypeptide sequences for DENV-1, DENV-2, DENV-3 and DENV-4. Also disclosed are dengue virus E protein fragments (such as the E protein ectodomain and DIII domain) fused to the molecular adjuvant P28. The disclosed nucleic acid and polypeptide sequences can be used as vaccines for immunization against dengue virus infection. In some cases, the vaccine includes a virus-like particle containing the universal dengue virus E protein, or fragment thereof, or the vaccine is a DNA molecule encoding the VLP.Type: GrantFiled: May 23, 2011Date of Patent: March 31, 2015Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Ted M. Ross, Nikolaos Vasilakis
-
Publication number: 20150079077Abstract: The present disclosure provides inter alia compositions that comprise therapeutic agents (e.g., live attenuated viral antigens, therapeutic proteins, etc.) and a lipid component. The lipid component may comprise or consist of different types of lipid or lipids as described herein. In some embodiments the therapeutic agents are thermolabile. The present disclosure also provides methods for preparing compositions, including the aforementioned compositions (e.g., melt methods and spray injection methods among others).Type: ApplicationFiled: January 25, 2013Publication date: March 19, 2015Inventors: Marc J. Kirchmeier, David E. Anderson
-
Patent number: 8968996Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be administered to a subject in different anatomical locations in order to induce a rapid response to all dengue virus serotypes. In certain embodiments, administration of two or more vaccine compositions to a subject against all dengue virus serotypes may include two or more routes of administration.Type: GrantFiled: June 10, 2012Date of Patent: March 3, 2015Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
-
Publication number: 20150056246Abstract: The present invention relates to a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides. Probiotic-derived vesicles displaying this fusion protein as well as methods of inducing an immune response using the probiotic cells or vesicles are also disclosed.Type: ApplicationFiled: March 13, 2013Publication date: February 26, 2015Inventors: David A. Putnam, Joseph Rosenthal, Chung-Jr Huang, Matthew Delisa, Susana Mendez
-
Patent number: 8961995Abstract: The present invention provides alphavirus replicons and methods of their use in producing heterologous protein.Type: GrantFiled: March 7, 2013Date of Patent: February 24, 2015Assignee: UAB Research FoundationInventors: Ilya Frolov, Elena Frolova
-
Patent number: 8961994Abstract: Aspects of the present invention relate to isolated nucleic acids that encode a consensus DIII domain of protein E and vaccines made using same, and also methods for using the aforementioned to generate in a host an immune response against multiple serotypes of flavivirus, particularly West Nile virus and Japanese encephalitis virus.Type: GrantFiled: November 17, 2009Date of Patent: February 24, 2015Assignee: VGX Pharmaceuticals, LLCInventors: Mathura P. Ramanathan, Niranjan Y Sardesai
-
Publication number: 20150037355Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.Type: ApplicationFiled: January 4, 2012Publication date: February 5, 2015Applicants: SILLAJEN, INC., JENNEREX INC.Inventors: David Kirn, John Bell, Caroline Breitback, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim
-
Publication number: 20150024002Abstract: Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as well as to method of making and using these immunogenic compositions.Type: ApplicationFiled: August 20, 2014Publication date: January 22, 2015Inventors: Silvia Perri, John Polo, Yasushi Uematsu, Catherine Greer
-
Publication number: 20150024004Abstract: The invention provides flavivirus vaccines and methods of making and using these vaccines.Type: ApplicationFiled: October 6, 2014Publication date: January 22, 2015Inventors: Thomas P. MONATH, Farshad GUIRAKHOO, Juan ARROYO, Konstantin V. PUGACHEV
-
Publication number: 20150017207Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.Type: ApplicationFiled: July 9, 2014Publication date: January 15, 2015Applicant: University of Washington through its Center for CommercializationInventors: Michael J. Gale, JR., Gretja Schnell, Yueh-Ming Loo
-
Patent number: 8932606Abstract: The construction of a chimeric Pestivirus by the identification of selected regions in the 3?NTR of the viral RNA genome is described where additional RNA sequences can be stably inserted. These sequence insertions in the viral RNA genome were stable in replication and capable of forming infectious, RNase resistant virus particles. This chimeric Pestivirus with a 3?NTR insertion can be utilized as a quality control material in analytical assays for RNA targets, including external, internal controls, quantitative standards in PCR and NAT nucleic acid assays.Type: GrantFiled: November 24, 2009Date of Patent: January 13, 2015Assignee: Life Technologies CorporationInventors: Erhard Schoenbrunner, Sven-Erik Behrens
-
Patent number: 8920804Abstract: The present invention provides monoclonal antibodies that are specific for the Dengue non-structural glycoprotein NS1 in monomeric and/or oligomeric (primarily dimeric) form, together with methods, including ELISA and lateral flow assays, that employ the disclosed antibodies for the early detection of Dengue virus infection. Diagnostic kits for the detection of Dengue infection are also provided, such kits including the disclosed monoclonal and/or polyclonal antibodies.Type: GrantFiled: September 27, 2012Date of Patent: December 30, 2014Assignee: InBios International, Inc.Inventors: Syamal Raychaudhuri, Raymond L. Houghton, Stanislaw Morkowski, Yvonne Stevens, Mohua Bose, James William Needham, Hongjing Chen
-
Patent number: 8920813Abstract: The invention relates to a replication-deficient adenoviral vector comprising two or more nucleic acid sequences encoding Dengue virus antigens and a chimeric hexon protein. The chimeric hexon protein comprises a first portion and a second portion. The first portion comprises at least 10 contiguous amino acid residues from a first adenovirus serotype (e.g., serotype 5 adenovirus hexon protein), optionally with one amino acid substitution. The second portion comprises (a) at least one hypervariable region (HVR) of a hexon protein of an adenovirus of a second adenovirus serotype, or (b) at least one synthetic hypervariable region (HVR) that is not present in the hexon protein of the wild-type adenovirus of the first adenovirus serotype.Type: GrantFiled: December 20, 2011Date of Patent: December 30, 2014Assignee: GenVec, Inc.Inventors: Joseph T. Bruder, Duncan McVey, Douglas E. Brough
-
Patent number: 8911744Abstract: The invention relates to a recombinant classical swine fever virus (CSFV). A preferred recombinant CSFV comprises a deletion of at least one amino acid in a “TAVSPTTLR” domain of the E2 protein. The invention further relates to a vaccine comprising the recombinant CSFV, a method for generating a recombinant CSFV, and use of a recombinant CSFV.Type: GrantFiled: December 23, 2009Date of Patent: December 16, 2014Assignee: Intervet International B.V.Inventors: Jeroen Alexander Kortekaas, Rianka Petronella Maria Vloet
-
Patent number: 8911738Abstract: Provided are human binding molecules that specifically bind to a host cell protein and have virus neutralizing activity, nucleic acid molecules encoding such human binding molecules, compositions comprising the human binding molecules, and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of viral infections.Type: GrantFiled: August 25, 2011Date of Patent: December 16, 2014Assignee: Crucell Holland B.V.Inventors: Mark Throsby, Cornelis A. de Kruif
-
Publication number: 20140356408Abstract: Biopharmaceuticals, such as vaccine agents and probiotics, are encapsulated in carbohydrate-glass particles and embedded in an amorphous polymer substrate to produce polymeric compositions containing ambient-temperature stable biopharmaceuticals for syringeless administration to patients such as via dissolvable films, micro-needle patches and similar medical delivery devices. The amorphous polymer substrate is soluble in both water and volatile organic solvents, yet the carbohydrate-glass particles are insoluble in organic solvents. A method for formulation of the polymeric compositions containing ambient-temperature stable biopharmaceuticals includes combining biopharmaceuticals encapsulated in carbohydrate-glass particles with polymer in organic solvent and evaporating the organic solvent to yield a water soluble polymeric composition containing ambient-temperature stable biopharmaceuticals.Type: ApplicationFiled: May 30, 2014Publication date: December 4, 2014Inventor: Victor Bronshtein
-
Patent number: 8900596Abstract: Provided herein is a computational method for designing a PCP-consensus protein for a family of related proteins. The method uses a consensus alignment of a protein domain common to all the related proteins, which may or may not be substantially biased, from which an average value of p, e.g., 5, physicochemical properties are calculated for each amino acid in the alignment. The PCP-consensus protein has a sequence derived from an alignment of protein domains from a family of related proteins, said sequence containing one or more motifs common to all of the proteins. Also provided are the PCP-consensus proteins, kits comprising the same, datasets of aligned consensus sequences used to derive the PCP-consensus proteins and methods of eliciting an immune response, diagnosing or treating an infectious disease using the same.Type: GrantFiled: November 18, 2010Date of Patent: December 2, 2014Assignee: The Board of Regents of the University of Texas SystemInventors: Catherine H. Schein, Petr Danecek
-
Patent number: 8895286Abstract: This invention relates to attenuated pestiviruses characterized in that their enzymatic activity residing in glycoprotein ERNS is inactivated, as well as methods of preparing, using and detecting these pestiviruses.Type: GrantFiled: May 5, 2011Date of Patent: November 25, 2014Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Gregor Meyers
-
Patent number: 8895028Abstract: The present invention provides a nucleic acid molecule comprising a nucleotide sequence encoding an infectious RNA molecule encoding a live viral strain of a dengue 3 virus (DV3), wherein said nucleotide sequence is the nucleotide sequence of SEQ ID NO:1 or a nucleotide sequence having at least 99% identity with the nucleotide sequence of SEQ ID NO.1.Type: GrantFiled: March 7, 2013Date of Patent: November 25, 2014Assignee: Arbovax, Inc.Inventors: Katherine M. Smith, Raquel Hernandez
-
Patent number: 8889148Abstract: Methods and compositions concerning mutant flaviviruses with host-range phenotypes are provided. Nucleotide sequences that encode mutant flavivirus proteins are also provided. In certain aspects, viruses comprising these sequences display reduced replication in mammalian cells. In further aspects of the invention, flavivirus vaccine compositions and methods for vaccination against flavivirus infection are provided.Type: GrantFiled: June 30, 2011Date of Patent: November 18, 2014Assignee: Research Development FoundationInventors: Dennis T. Brown, Raquel Hernandez
-
Patent number: 8889845Abstract: Compositions and methods for the detection, diagnosis and treatment of BVDV and other viruses are provided.Type: GrantFiled: June 3, 2010Date of Patent: November 18, 2014Assignee: University of WyomingInventors: Thomas R. Hansen, Kathleen J. Austin, Alberto van Olphen, Lea A. Rempel
-
Publication number: 20140328877Abstract: The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates.Type: ApplicationFiled: April 11, 2014Publication date: November 6, 2014Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Kristina J. HENNESSY, Phillip Wayne HAYES
-
Publication number: 20140322270Abstract: The invention provides a an inactive, non-replicating vaccine comprising whole virion, chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.Type: ApplicationFiled: May 2, 2014Publication date: October 30, 2014Applicant: GE HEALTHCARE BIO-SCIENCES CORP.Inventors: CYNTHIA K. LEE, THOMAS P. MONATH, PATRICK M. GUERTIN, EDWARD G. HAYMAN
-
Patent number: 8871222Abstract: The invention provides recombinant flavivirus vaccines that can be used in the prevention and treatment of flavivirus infection. The vaccines of the invention contain recombinant flaviviruses including attenuating mutations.Type: GrantFiled: February 27, 2012Date of Patent: October 28, 2014Assignee: Sanofi Pasteur Biologics, LLCInventors: Konstantin V. Pugachev, Farshad Guirakhoo, Thomas P. Monath
-
Patent number: 8871487Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.Type: GrantFiled: December 4, 2009Date of Patent: October 28, 2014Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Jill A. Livengood, O'Neil Wiggan, Richard Kinney, Jorge Osorio
-
Publication number: 20140314739Abstract: The present invention provides a composition comprising or consisting of inulin particles for use in the reduction or inhibition of inflammation, and/or for treating or preventing inflammatory disease, in a subject. Also provided is a pharmaceutically acceptable composition comprising: particles of inulin; and a substance comprising or consisting of one or more pathogen-associated molecular patterns (PAMPs), or an equivalent kit of parts, and methods and uses of the composition and kit for inducing or modulating an immune response in a subject, such as modulating an immune response to an antigen or allergen and/or as a vaccine. Also provided is a single-dose vaccine composition comprising inulin particles, an antigen and, optionally, an antigen-binding carrier material, and methods and uses of the vaccine.Type: ApplicationFiled: June 19, 2012Publication date: October 23, 2014Applicant: Vaxine Pty Ltd.Inventor: Nikolai Petrovsky
-
Publication number: 20140314810Abstract: The invention provides methods of producing vaccines directed against methicillin-resistant Staphylococcus aureus (MRSA) or Venezuelan equine encephalitis virus (VEEV), with the methods comprising culturing, harvesting and/or suspending the MRSA or VEEV in the presence of a radiation-protective composition and irradiating the MRSA with a dose of radiation sufficient to render the MRSA or VEEV replication-deficient and/or non-infective. The radiation-protective compositions used in the methods of the present invention comprise at least one nucleoside, at least one antioxidant and at least one small peptide.Type: ApplicationFiled: November 1, 2012Publication date: October 23, 2014Applicant: United States Department of Health and Human ServicesInventors: Michael Daly, Elena K Gaidamakova, Ian A. Myles, Patricia A. Valdez, Sandip K. Datta
-
Patent number: 8865178Abstract: The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osetoarthritic diseases, or diabetes). In particular, the present invention provides compositions and methods comprising molecules with linked ?-gal epitopes for induction of recruitment of macrophages localized within or surrounding damaged tissue. The recruited macrophages recruit stem cells and promote the repair and regeneration of the treated injured tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects. In some embodiments, the present invention provides treatments for injured tissues such as brain, peripheral nerve, heart muscle, skeletal muscle, cartilage, bone, gastrointestinal tract and dysfunctional endocrine tissues.Type: GrantFiled: August 17, 2010Date of Patent: October 21, 2014Assignee: University of MassachusettsInventor: Uri Galili
-
Patent number: 8865184Abstract: The present invention relates to vaccine formulation capable of eliciting protective immune response against Chikungunya virus infection in humans and other mammalian hosts. The immunogenic formulation comprises purified inactivated Chikungunya virus in a stable formulation. Methods of propagation and purification of the virus are discussed. The inactivated virus formulation is non-infectious, immunogenic and elicits protective immune response in mammalian host. The immunogenic composition is formulated for in vivo administration to humans. The invention also discusses the strategy of developing a subunit vaccine using the recombinant viral proteins as antigens for immunization. The recombinant virus antigens that are potentially immunogenic can be used in diagnosing for the presence of the virus.Type: GrantFiled: August 31, 2007Date of Patent: October 21, 2014Assignee: Bharat Biotech International LimitedInventors: Murthy Krishna Ella, Kandaswamy Sumathy, Jaya Sheela Pydigummala, Nagendra R. Hegde
-
Publication number: 20140302091Abstract: Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.Type: ApplicationFiled: November 18, 2011Publication date: October 9, 2014Inventors: Dan T. Stinchcomb, Jorge E. Osorio, O'Neil Wiggan
-
Patent number: 8852609Abstract: Consensus CHIKV E1 protein, consensus CHIKV E2 protein, consensus CHIKV capsid protein, or fragments and homologues thereof, and nucleic acid molecules that encode the same are disclosed. A consensus CHIKV Env protein which includes CHIKV E1 consensus protein, CHIKV E2 consensus protein, CHIKV E3 consensus protein, or fragments and homologues thereof and nucleic acid molecules that encode the same are also disclosed. Compositions and recombinant vaccines comprising CHIKV consensus proteins, and methods of using them are disclosed.Type: GrantFiled: April 6, 2009Date of Patent: October 7, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: David B. Weiner, Karuppiah Muthumani
-
Patent number: 8852914Abstract: The invention provides flavivirus vaccines and methods of making and using these vaccines.Type: GrantFiled: November 5, 2012Date of Patent: October 7, 2014Assignee: Sanofi Pasteur Biologics, LLCInventors: Thomas P. Monath, Farshad Guirakhoo, Juan Arroyo, Konstantin V. Pugachev
-
Patent number: 8846051Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.Type: GrantFiled: October 7, 2005Date of Patent: September 30, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Olen M. Kew, Cara C. Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
-
Publication number: 20140271709Abstract: The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, and a sugar alcohol. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.Type: ApplicationFiled: March 10, 2014Publication date: September 18, 2014Inventors: Brad Eddy, Zhisong QIAO, Kevin O'Connell
-
Publication number: 20140271714Abstract: The invention relates to methods for the induction of an immune response to dengue virus. The method of inducing an immune response against dengue virus comprises administration of a non-replicating immunogen followed by a boost with a tetravalent live attenuated viral vaccine. Another aspect of the inventive subject matter is a method of inducing an immune response against dengue virus using a heterologous prime-boost regimen with the priming immunogen comprising a DNA expression system, an adenovirus expression vector or a Venezuelan equine encephalitis virus replicon system and the boosting immunogen comprising the same without the DNA expression system. Each expression system contains DNA sequences encoding dengue viral proteins.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Inventors: Monika Simmons, Kevin R. Porter, Kanakatte Raviprakash, Wellington Sun
-
Publication number: 20140271715Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: INVIRAGEN, INC.Inventors: Daniel T. Stinchcomb, Jill A. Livengood, Lazlo Varga
-
Patent number: 8835620Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal.Type: GrantFiled: January 12, 2009Date of Patent: September 16, 2014Assignee: VGX Pharmaceuticals, LLCInventors: Mathura P. Ramanathan, Niranjan Sardesai
-
Patent number: 8828687Abstract: The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in the vector virus, they present in the 5? region, nucleotides present in the 5? edge of the gene NS1 of this vector virus or of other virus or equivalent functional sequences, and in its 3? region, the correspondent genome region in the whole or part of the spheres of the steam and anchor of the protein E of this vector virus or equivalent functional sequences, and not compromising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein E level and of on structural NS1 vector virus; (c) obtention of the non pathogenic recombinant virus and owner of the immunologic properties, havingType: GrantFiled: October 31, 2006Date of Patent: September 9, 2014Inventors: Myrna Cristina Bonaldo, Ricardo Galler
-
Patent number: 8821897Abstract: The present invention provides viral adjuvants for enhancing an immune response to an immunogen. In particular embodiments, the viral adjuvant is an alphavirus adjuvant or a Venezuelan Equine Encephalitis viral adjuvant. Also provided are compositions comprising the viral adjuvant and an immunogen, and pharmaceutical formulations comprising the viral adjuvant or compositions of the invention in a pharmaceutically acceptable carrier. Further provided are methods of producing an immune response against an immunogen in a subject comprising administering the immunogen and a viral adjuvant of the invention to the subject.Type: GrantFiled: November 24, 2010Date of Patent: September 2, 2014Assignee: The University of North Carolina at Chapel HillInventors: Robert E. Johnston, Joseph M. Thompson
-
Patent number: RE45123Abstract: The invention provides compositions featuring an attenuated dengue virus mutant or an attenuated chimeric dengue virus mutant.Type: GrantFiled: May 17, 2013Date of Patent: September 9, 2014Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai